Ningbo Tianyi Medical initiates its first share repurchase, spending to buy back 80,000 shares, representing 0.1357% of the total share capital.

Log in to Sina Finance App and search for [Information Disclosure] to see more evaluation levels.

Ningbo Tianyi Medical Equipment Co., Ltd. (hereinafter referred to as “Ningbo Tianyi Medical”) disclosed on March 19, 2026, the “Announcement on the First Share Repurchase and Progress of Share Repurchase,” stating that the company completed its first share repurchase on March 17 through the Shenzhen Stock Exchange trading system via centralized bidding, with a total of 80,000 shares repurchased, accounting for 0.1357% of the company’s current total share capital. This repurchase marks the official implementation phase of the company’s previously disclosed share repurchase plan.

Review of the Repurchase Plan

According to the announcement, Ningbo Tianyi Medical held the second meeting of the fourth board of directors on January 12, 2026, and approved the share repurchase plan. The plan proposes to use self-owned funds and bank loans to repurchase some A-shares through centralized bidding, for implementing equity incentives or employee stock ownership plans. The specific parameters are as follows:

Details of the First Repurchase

The announcement disclosed that on March 17, 2026, the company repurchased 80,000 shares through centralized bidding, representing 0.1357% of the company’s current total share capital of 58,947,368 shares. This repurchase was carried out strictly according to the approved plan and relevant regulatory requirements, complying with the “Rules for Share Repurchase of Listed Companies (2025 Revision)” and the “Shenzhen Stock Exchange Listed Company Self-Regulatory Guidelines No. 9 — Share Repurchase (2025 Revision).”

Compliance Statement

The company emphasizes that the timing, quantity, price, and entrusted period of the first share repurchase all comply with regulatory requirements. Specifically, the repurchase was not conducted during prohibited periods such as “major events that may significantly impact securities trading prices or decision-making processes until disclosure,” and the entrusted price did not reach the daily trading limit, nor was it carried out during opening or closing auction sessions or on days without price fluctuation limits.

Follow-up Plan

The announcement states that the company will continue to implement this repurchase plan within the repurchase period based on market conditions and will fulfill information disclosure obligations in a timely manner according to relevant regulations. Market analysts believe that the implementation of this repurchase plan demonstrates the company’s confidence in its future development prospects and helps stabilize investor expectations.

As of the disclosure date, Ningbo Tianyi Medical’s total share capital is 58,947,368 shares. After this initial repurchase, the company will continue to disclose relevant information based on the progress of the repurchase, and investors are advised to follow the company’s subsequent announcements to understand the implementation status of the plan.

Disclaimer: The market carries risks; investment should be cautious. This article is automatically published by an AI model based on third-party databases and does not represent Sina Finance’s views. Any information appearing herein is for reference only and does not constitute personal investment advice. Please refer to the actual announcement for accuracy. If you have any questions, contact biz@staff.sina.com.cn.

Click here to view the original announcement >>